search

Active clinical trials for "Clostridium Infections"

Results 31-40 of 285

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

Clostridium Difficile Infection

Segments 2A and 2B of this trial evaluate the safety, efficacy, pharmacokinetics, fecal concentrations, and fecal microbiome effects of ACX-362E [ibezapolstat] in patients with C. difficile infection (CDI).

Active34 enrollment criteria

Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection

Clostridium Difficile InfectionClostridioides Difficile Infection

Clostridioides difficile (CD) infection (CDI) is a global health threat with an urgent need for new treatment strategies. Faecal microbiota transplantation (FMT) is effective for recurrent Clostridioides difficile infection (CDI), and is currently recommended for multiple (three or more), recurrent CDI infections. The role of FMT earlier in the treatment hierarchy of CDI remains to be determined. In this randomized, double-blinded, placebo-controlled clinical trial, we compare FMT with placebo following standard antibiotic treatment for first or second Clostridioides difficile infection.

Active11 enrollment criteria

Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile...

Allogeneic Hematopoietic Stem Cell

The purpose of this study is to see if fecal microbiota transplantation (FMT) will prevent the future development of CDI. This is also known as fecal bacteriotherapy or stool transplant.

Active4 enrollment criteria

Addressing Personalized Needs in Clostridioides Difficile Infection

Clostridioides Difficile Infection

BEYOND is aiming to demonstrate how by enrichment of the available SPECIFY score, patients at great likelihood for CDI with unfavorable outcome are early detected

Recruiting5 enrollment criteria

L. Plantarum 299v and Gut Microbiome, Diarrhoea, and Clostridioides Difficile Infection in Colorectal...

Colorectal CancerClostridioides Difficile Infection1 more

Colorectal cancer in periooperative period patients (n=60) will be enrolled to this study. Participants will be divided into 4 groups as follows: group 1 (n=15) will receive 2 capsules (per day) of L. plantarum 299v L. plantarum 299v (Sanprobi IBS®) for 4 weeks group 2 (n=15) will receive L. plantarum 299v (2 capsules per day) and inulin (4 g) for 4 weeks group 3 (n=15) will receive placebo (2 capsules per day) and inulin (4 g) for 4 weeks group 4 (n=15) will receive placebo (2 capsules per day) for 4 weeks

Recruiting10 enrollment criteria

Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection...

Clostridium Difficile ColonizationClostridium Difficile Diarrhea

The goal of this pilot study is to assess the feasibility of randomizing hospitalized patients that are colonized with C. difficile and started on systemic antibiotics to either a probiotic, oral vancomycin, or placebo in a parallel-group 1:1:1 design. The ultimate goal is to conduct an appropriately-powered RCT to determine the optimal method for reducing C difficile infection in colonized patients.

Recruiting15 enrollment criteria

Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections

Intestinal InfectionClostridioides Difficile Infection1 more

A national data registry of patients receiving the rescue fecal microbiota transplantation for the refractory intestinal infections from the China Microbiota Transplantation System was designed to assess the short-term and long-term safety and efficacy.

Recruiting2 enrollment criteria

High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology...

LeukemiaLymphocytic6 more

The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduces C. difficile infection recurrence in a cohort of oncology patients.

Recruiting6 enrollment criteria

Fecal Microbiota Transplant National Registry

Fecal Microbiota TransplantationClostridium Difficile Infection1 more

A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness

Recruiting8 enrollment criteria

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

Inflammatory Bowel DiseasesClostridioides Difficile Infection

This is a randomized placebo controlled study to assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in IBD patients. A total of 72 patients who meet eligibility criteria will be randomized 1:1 to either the xylitol or sucralose (placebo) arm. Both arms will receive a dose comprising five capsules BID for four weeks. Microbiome assessment and C. difficile testing will be performed at baseline, week 4, 8, 26, and 52.

Not yet recruiting10 enrollment criteria
1...345...29

Need Help? Contact our team!


We'll reach out to this number within 24 hrs